Abstract |
Cytarabine-based immuno- chemotherapy followed by autologous stem cell transplantation (ASCT) consolidation is standard of care for fit patients with Mantle Cell Lymphoma (MCL). BEAM ( Carmustine, Etoposide, Aracytine, Melphalan) is among the most frequently used conditioning regimen. Studies comparing BEAM with Bendamustine-EAM (BeEAM) have suggested that patients treated with BeEAM have a better progression-free survival (PFS). We performed a cross-study analysis to better evaluate BeEAM. Thirty-five patients from a retrospective study who received R-DHAP/BeEAM were compared to 245 patients from the LyMa trial (NCT00921414) who all received R-DHAP followed by R-BEAM. PFS and Overall Survival (OS) were estimated using Kaplan-Meier methods. At 2 years there was no difference between R-BEAM and BeEAM in either PFS (84.9% versus 87.9%; p = 0.95) or OS (91.8% versus 94.2%; p = 0.30). Analyses were repeated on a propensity score to reduce biases. Each patient from the BeEAM cohort (n = 30) was matched to three patients from the R-BEAM cohort (n = 90) for age, sex, MIPI score, pre-transplant status disease and rituximab maintenance (RM). PFS and OS at 2 years remained similar between R-BEAM and BeEAM with more renal toxicity in BeEAM group. MCL patients who received R-DHAP induction before ASCT have similar outcome after R-BEAM or BeEAM conditioning regimen.
|
Authors | Domitille Costes-Tertrais, Thomas Hueso, Thomas Gastinne, Catherine Thieblemont, Lucie Oberic, Krimo Bouabdallah, Sylvain Garciaz, Emmanuelle Tchernonog, Caroline Dartigeas, Vincent Ribrag, Patrick Fogarty, René-Olivier Casasnovas, Roch Houot, Caroline Delette, Sandra Malak, Luc-Matthieu Fornecker, Remy Gressin, Gandhi Damaj, Steven Le Gouill |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 57
Issue 4
Pg. 627-632
(04 2022)
ISSN: 1476-5365 [Electronic] England |
PMID | 35149851
(Publication Type: Journal Article)
|
Copyright | © 2022. The Author(s), under exclusive licence to Springer Nature Limited. |
Chemical References |
- Cytarabine
- Etoposide
- Bendamustine Hydrochloride
- Melphalan
- Carmustine
|
Topics |
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bendamustine Hydrochloride
(therapeutic use)
- Carmustine
(pharmacology, therapeutic use)
- Cytarabine
(therapeutic use)
- Etoposide
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Lymphoma, Mantle-Cell
(drug therapy)
- Melphalan
(therapeutic use)
- Retrospective Studies
- Transplantation, Autologous
(methods)
|